Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma
{{output}}
Cutaneous metastases occur in up to 20% of patients with advanced melanoma and can be difficult to manage with systemic therapy alone. Pembrolizumab is a standard therapy with limited local treatment options for cutaneous manifestations. Imiquimod has shown ac... ...
